Marineci Cristian Daniel, Valeanu Andrei, Chiriță Cornel, Negreș Simona, Stoicescu Claudiu, Chioncel Valentin
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 020956 Bucharest, Romania.
Department of Cardiology, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Medicina (Kaunas). 2025 Jul 21;61(7):1313. doi: 10.3390/medicina61071313.
: Investigating the adherence to antihypertensive medication and identifying patients with low adherence allows targeted interventions to improve therapeutic outcomes. Artificial intelligence (AI) offers advanced tools for analyzing medication adherence data. This study aimed to develop and validate several predictive models for non-adherence, using patient-reported data collected via a structured questionnaire. : A cross-sectional, multi-center study was conducted on 3095 hypertensive patients from community pharmacies. A structured questionnaire was administered, collecting data on sociodemographic factors, medical history, self-monitoring behaviors, and informational exposure, alongside medication adherence measured using the Romanian-translated and validated ARMS (Adherence to Refills and Medications Scale). Five machine learning models were developed to predict non-adherence, defined by ARMS quartile-based thresholds. The models included Logistic Regression, Random Forest, and boosting algorithms (CatBoost, LightGBM, and XGBoost). Models were evaluated based on their ability to stratify patients according to adherence risk. : A total of 79.13% of respondents had an ARMS Score ≥ 15, indicating a high prevalence of suboptimal adherence. Better adherence was statistically associated (adjusted for age and sex) with more frequent blood pressure self-monitoring, a reduced salt intake, fewer daily supplements, more frequent reading of medication leaflets, and the receipt of specific information from pharmacists. Among the ML models, CatBoost achieved the highest ROC AUC Scores across the non-adherence classifications, although none exceeded 0.75. : Several machine learning models were developed and validated to estimate levels of medication non-adherence. While the performance was moderate, the results demonstrate the potential of AI in identifying and stratifying patients by adherence profiles. Notably, to our knowledge, this study represents the first application of permutation and SHapley Additive exPlanations feature importance in combination with probability-based adherence stratification, offering a novel framework for predictive adherence modelling.
研究抗高血压药物的依从性并识别依从性低的患者,有助于进行有针对性的干预,以改善治疗效果。人工智能(AI)为分析药物依从性数据提供了先进工具。本研究旨在利用通过结构化问卷收集的患者报告数据,开发并验证几种预测不依从性的模型。
对来自社区药房的3095名高血压患者进行了一项横断面、多中心研究。采用结构化问卷,收集社会人口学因素、病史、自我监测行为和信息接触情况的数据,同时使用罗马尼亚语翻译并验证的ARMS(药品续方和用药依从性量表)来测量药物依从性。开发了五个机器学习模型来预测不依从性,不依从性由基于ARMS四分位数的阈值定义。这些模型包括逻辑回归、随机森林和提升算法(CatBoost、LightGBM和XGBoost)。根据模型对患者依从性风险进行分层的能力对模型进行评估。
共有79.13%的受访者ARMS评分≥15,表明次优依从性的患病率较高。在对年龄和性别进行调整后,更好的依从性在统计学上与更频繁的血压自我监测、减少盐摄入量、减少每日补充剂服用、更频繁阅读药品说明书以及从药剂师处获得特定信息相关。在机器学习模型中,CatBoost在所有不依从性分类中获得了最高的ROC AUC分数,尽管没有一个超过0.75。
开发并验证了几种机器学习模型,以估计药物不依从性水平。虽然性能中等,但结果证明了人工智能在根据依从性概况识别和分层患者方面的潜力。值得注意的是,据我们所知,本研究首次将排列和SHapley加性解释特征重要性与基于概率的依从性分层相结合,为预测依从性建模提供了一个新框架。